Belite Bio (BLTE) Consolidated Net Income (2022 - 2026)

Belite Bio's Consolidated Net Income history runs 5 years deep, the most recent figure standing at -$26.9 million for Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 88.68% year-over-year to -$26.9 million in Q1 2026; TTM through Mar 2026 was -$63.4 billion, a 124.04% decrease from a year earlier, with the FY2025 full-year figure at -$77.5 million, down 131.85% from the prior year.
• Consolidated Net Income grew to -$26.9 million in Q1 2026 per BLTE's latest filing, from -$25.3 billion in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$6.8 million in Q4 2022 and bottomed at -$25.3 billion in Q4 2025.
• The 5-year median for Consolidated Net Income is -$6.9 billion (2023), against an average of -$7.4 billion.
• Across the five-year window, Consolidated Net Income plunged 144392.13% in 2024 and soared 99.82% in 2025, its largest moves.
• Year by year, Consolidated Net Income stood at -$6.8 million in 2022, then declined by 3.05% to -$7.0 million in 2023, then plunged by 144392.13% to -$10.1 billion in 2024, then tumbled by 150.73% to -$25.3 billion in 2025, then jumped by 99.89% to -$26.9 million in 2026.
• Per Business Quant, the three latest BLTE Consolidated Net Income figures stand at -$26.9 million (Q1 2026), -$25.3 billion (Q4 2025), and -$21.7 billion (Q3 2025).